Jan 11, 2023 / 01:15AM GMT
Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst
Hello. My name is Daniel Wolle. I'm one of the SMid-Cap Biotech Analyst at JPM. It's my pleasure to introduce Karim Mikhail from Amarin. Without further ado.
Karim Mikhail - Amarin Corporation plc - President, CEO & Director
Good afternoon, everyone. I just want to start by thanking Daniel and JPMorgan for inviting us for the conference to share with you the progress we've made in 2020, '22 against solid through bold objectives that we've had. 2022 started as a challenging year where we've had the third generic, we had an impact on revenue. But we are closing the year with 4 consecutive quarters of revenue in the U.S., a positive cash burn in Q4, but also 5 markets where we have final pricing and reimbursement in Europe. So in my presentation, I may make forward-looking statements or a full list of risk factors, please consult our SEC filing.
So my presentation is going to have 4 main portions. I will start first by just reviewing a little bit of the Amarin journey, where we have
Amarin Corporation PLC at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers